0001439222-24-000020.txt : 20240124
0001439222-24-000020.hdr.sgml : 20240124
20240124162424
ACCESSION NUMBER: 0001439222-24-000020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240120
FILED AS OF DATE: 20240124
DATE AS OF CHANGE: 20240124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gheuens Sarah
CENTRAL INDEX KEY: 0001881190
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36014
FILM NUMBER: 24556809
MAIL ADDRESS:
STREET 1: C/O AGIOS PHARMACEUTICALS, INC.
STREET 2: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001439222
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-8600
MAIL ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20080703
4
1
wk-form4_1706131453.xml
FORM 4
X0508
4
2024-01-20
0
0001439222
AGIOS PHARMACEUTICALS, INC.
AGIO
0001881190
Gheuens Sarah
88 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
1
Common stock
2024-01-20
4
M
0
5750
0
A
33619
D
Common stock
2024-01-24
4
S
0
1708
21.64
D
31911
D
Performance share units
2024-01-20
4
M
0
5750
0
D
Common stock
5750
0
D
Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022.
Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
The PSUs were granted on March 1, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
/s/ William Cook, as attorney-in-fact for Sarah Gheuens
2024-01-24